Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other Accumulated Expenses: 2019-2025

Historic Other Accumulated Expenses for Summit Therapeutics (SMMT) over the last 6 years, with Sep 2025 value amounting to $2.0 million.

  • Summit Therapeutics' Other Accumulated Expenses rose 90.46% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 90.46%. This contributed to the annual value of $1.8 million for FY2024, which is 150.63% up from last year.
  • Latest data reveals that Summit Therapeutics reported Other Accumulated Expenses of $2.0 million as of Q3 2025, which was up 31.72% from $1.5 million recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' Other Accumulated Expenses registered a high of $2.0 million during Q3 2025, and its lowest value of $209,000 during Q3 2022.
  • In the last 3 years, Summit Therapeutics' Other Accumulated Expenses had a median value of $788,000 in 2024 and averaged $978,000.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first surged by 190.96% in 2021, then crashed by 79.71% in 2022.
  • Summit Therapeutics' Other Accumulated Expenses (Quarterly) stood at $897,000 in 2021, then fell by 26.20% to $662,000 in 2022, then increased by 8.31% to $717,000 in 2023, then surged by 150.63% to $1.8 million in 2024, then surged by 90.46% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $1.5 million for Q2 2025, and $759,000 during Q1 2025.